Recognition of different subsets of alloreactive T cells by activation-induced markers., PMID:40204006
Activation of immune checkpoint OX40 inhibits HBV replication in a mouse model., PMID:39923582
Tumor-Infiltrating Immune Cells and HLA Expression as Potential Biomarkers Predicting Response to PD-1 Inhibitor Therapy in Stage IV Melanoma Patients., PMID:39766316
A Phase I Clinical Trial Adding OX40 Agonism to In Situ Therapeutic Cancer Vaccination in Patients with Low-Grade B-cell Lymphoma Highlights Challenges in Translation from Mouse to Human Studies., PMID:39745391
SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity., PMID:39543823
Making the effect visible - OX40 targeting nanobodies for in vivo imaging of activated T cells., PMID:39474429
From structural design to delivery: mRNA therapeutics for cancer immunotherapy., PMID:38855617
The Role of OX40-OX40L Axis in the Pathogenesis of Atopic Dermatitis., PMID:38700255
Regulation of the Function of T Follicular Helper Cells and B Cells in Type 1 Diabetes Mellitus by the OX40/OX40L Axis., PMID:38625053
An OX-Tra'Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis., PMID:38607026
OX40/OX40 ligand and its role in precision immune oncology., PMID:38526805
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target., PMID:38236520
Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer., PMID:38140230
SARS-CoV-2 Variants Omicron BA.4/5 and XBB.1.5 Significantly Escape T Cell Recognition in Solid-organ Transplant Recipients Vaccinated Against the Ancestral Strain., PMID:38012843
BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy., PMID:37576888
Assessing SARS-CoV-2-specific T-cell reactivity in late convalescents and vaccinees: Comparison and combination of QuantiFERON and activation-induced marker assays, and relation with antibody status., PMID:37220145
Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome., PMID:37051254
The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer., PMID:36960067
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)., PMID:36927527
Multicentric IL-5-positive Castleman Disease With Nephrotic Syndrome Relapsed After Rituximab Treatment., PMID:36593046
In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity., PMID:35653749
Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses., PMID:35607995
Antigen-Specific CD4+ T-Cell Activation in Primary Antibody Deficiency After BNT162b2 mRNA COVID-19 Vaccination., PMID:35237272
Approaches of the Innate Immune System to Ameliorate Adaptive Immunotherapy for B-Cell Non-Hodgkin Lymphoma in Their Microenvironment., PMID:35008305
Anti-tumour effect of in situ vaccines combined with VEGFR inhibitors in the treatment of metastatic cervical cancer., PMID:34717193
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers., PMID:34615725
Immune Assessment of BNT162b2 m-RNA-Spike Based Vaccine Response in Adults., PMID:34440072
New Biologics for the Treatment of Atopic Dermatitis: Analysis of Efficacy, Safety, and Paradoxical Atopic Dermatitis Acceleration., PMID:34195265
Generation and characterization of a high-affinity chimeric anti-OX40 antibody with potent antitumor activity., PMID:33792041
Prolactin Increases the Frequency of Follicular T Helper Cells with Enhanced IL21 Secretion and OX40 Expression in Lupus-Prone MRL/lpr Mice., PMID:33763492
Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells., PMID:33729092
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design., PMID:33682447
Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist., PMID:33500260
Pro-inflammatory dopamine-2 receptor-specific T cells in paediatric movement and psychiatric disorders., PMID:33425355
Head-to-head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL2Rγnull mice reconstituted with human peripheral blood mononuclear cells., PMID:33293281
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors., PMID:33148673
Targeting co-stimulatory molecules in autoimmune disease., PMID:32939077
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells., PMID:32900860
Visualization of Activated T Cells by OX40-ImmunoPET as a Strategy for Diagnosis of Acute Graft-versus-Host Disease., PMID:32900772
Structural basis for the interaction of human herpesvirus 6B tetrameric glycoprotein complex with the cellular receptor, human CD134., PMID:32678833
New and Emerging Systemic Treatments for Atopic Dermatitis., PMID:32519223
Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis., PMID:36776497
New pathways in immune stimulation: targeting OX40., PMID:32392177
A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice., PMID:32326142
gp96 Is Critical for both Human Herpesvirus 6A (HHV-6A) and HHV-6B Infections., PMID:32295911
The OX40 Axis is Associated with Both Systemic and Local Involvement in Atopic Dermatitis., PMID:32176307
Development and characterization of a novel anti-OX40 antibody for potent immune activation., PMID:32078015
No Evidence for Circulating Retina Specific Autoreactive T-cells in Latent Tuberculosis-associated Uveitis and Sarcoid Uveitis., PMID:31913737
CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo., PMID:31807014
Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1., PMID:31216214
For research use only. Not for human or drug use.
